J. R. Wingard, N. S. Majhail, R. Brazauskas, Z. Wang, K. A. Sobocinski et al., Long-term survival and late deaths after allogeneic hematopoietic cell transplantation, J Clin Oncol, vol.29, issue.16, pp.2230-2239, 2011.

P. J. Martin, G. W. Counts, F. R. Appelbaum, S. J. Lee, J. E. Sanders et al., Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation, J Clin Oncol, vol.28, issue.6, pp.1011-1017, 2010.

C. J. Lee, S. Kim, H. R. Tecca, S. Bo-subait, R. Phelan et al., Late effects after ablative allogeneic stem cell transplantation for adolescent and young adult acute myeloid leukemia, Blood Adv, vol.4, issue.6, pp.983-92, 2020.

R. Zeiser and B. R. Blazar, Pathophysiology of chronic graft-versus-host disease and therapeutic targets, N Engl J Med, vol.377, issue.26, pp.2565-79, 2017.

R. Zeiser and B. R. Blazar, Acute graft-versus-host disease -biologic process, prevention, and therapy, N Engl J Med, vol.377, issue.22, pp.2167-79, 2017.

O. Penack, M. Marchetti, T. Ruutu, M. Aljurf, A. Bacigalupo et al., Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation, Lancet Haematol, vol.7, issue.2, pp.157-67, 2020.

J. Finke, W. A. Bethge, C. Schmoor, H. D. Ottinger, M. Stelljes et al., Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial, Lancet Oncol, vol.10, issue.9, pp.855-64, 2009.

J. Finke, C. Schmoor, W. A. Bethge, H. Ottinger, M. Stelljes et al., Longterm outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial, Lancet Haematol, vol.4, issue.6, pp.293-301, 2017.

I. Walker, T. Panzarella, S. Couban, F. Couture, G. Devins et al., Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial, Lancet Oncol, vol.17, issue.2, pp.164-73, 2016.

A. Bacigalupo, T. Lamparelli, P. Bruzzi, S. Guidi, P. E. Alessandrino et al., Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO), Blood, vol.98, issue.10, pp.2942-2949, 2001.

R. J. Soiffer, J. Lerademacher, V. Ho, F. Kan, A. Artz et al., Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies, Blood, vol.117, issue.25, pp.6963-70, 2011.

J. E. Wagner, J. S. Thompson, S. L. Carter, and N. A. Kernan, Unrelated Donor Marrow Transplantation T. Effect of graft-versus-host disease prophylaxis on 3-year diseasefree survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial, Lancet, vol.366, issue.9487, pp.733-774, 2005.

M. Mohty, Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond, Leukemia, vol.21, issue.7, pp.1387-94, 2007.

L. Luznik, P. V. O'donnell, H. J. Symons, A. R. Chen, M. S. Leffell et al., HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide, Biol Blood Marrow Transplant, vol.14, issue.6, pp.641-50, 2008.

A. Bashey, X. Zhang, C. A. Sizemore, K. Manion, S. Brown et al., T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLAmatched related and unrelated donor transplantation, J Clin Oncol, vol.31, issue.10, pp.1310-1316, 2013.

H. Mayumi and R. A. Good, Long-lasting skin allograft tolerance in adult mice induced across fully allogeneic (multimajor H-2 plus multiminor histocompatibility) antigen barriers by a tolerance-inducing method using cyclophosphamide, J Exp Med, vol.169, issue.1, pp.213-251, 1989.

M. Eto, H. Mayumi, Y. Tomita, Y. Yoshikai, Y. Nishimura et al., Sequential mechanisms of cyclophosphamide-induced skin allograft tolerance including the intrathymic clonal deletion followed by late breakdown of the clonal deletion, J Immunol, vol.145, issue.5, pp.1303-1313, 1990.

S. Ganguly, D. B. Ross, A. Panoskaltsis-mortari, C. G. Kanakry, B. R. Blazar et al., Donor CD4+ Foxp3+ regulatory T cells are necessary for posttransplantation cyclophosphamide-mediated protection against GVHD in mice, Blood, vol.124, issue.13, pp.2131-2172, 2014.

C. G. Kanakry, S. Ganguly, M. Zahurak, J. Bolanos-meade, C. Thoburn et al., Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide, Sci Transl Med, vol.5, issue.211, pp.211-157, 2013.

L. P. Wachsmuth, M. T. Patterson, M. A. Eckhaus, D. J. Venzon, R. E. Gress et al., Post-transplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression, J Clin Invest, vol.129, issue.6, pp.2357-73, 2019.

M. Mielcarek, T. Furlong, O. Donnell, P. V. Storer, B. E. Mccune et al., Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation, Blood, vol.127, issue.11, pp.1502-1510, 2016.

F. Carnevale-schianca, D. Caravelli, S. Gallo, V. Coha, D. 'ambrosio et al., Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination prevents graft-versus-host disease in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors, Biol Blood Marrow Transplant, vol.23, issue.3, pp.459-66, 2017.

A. S. Jorge, M. Suarez-lledo, A. Pereira, G. Gutierrez, F. Fernandez-aviles et al., Single antigen-mismatched unrelated hematopoietic stem cell transplantation using high-dose post-transplantation cyclophosphamide is a suitable alternative for patients lacking HLA-matched donors, Biol Blood Marrow Transplant, vol.24, issue.6, pp.1196-202, 2018.

A. Ruggeri, M. Labopin, A. Bacigalupo, B. Afanasyev, J. J. Cornelissen et al., Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT, J Hematol Oncol, vol.11, issue.1, p.40, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01762520

G. Battipaglia, M. Labopin, N. Kroger, A. Vitek, B. Afanasyev et al., Posttransplant cyclophosphamide vs antithymocyte globulin in HLAmismatched unrelated donor transplantation, Blood, vol.134, issue.11, pp.892-901, 2019.

D. Przepiorka, D. Weisdorf, P. Martin, H. G. Klingemann, P. Beatty et al., consensus conference on acute GVHD Grading, vol.15, pp.825-833, 1994.

S. J. Lee, G. Vogelsang, and M. E. Flowers, Chronic graft-versus-host disease, Biol Blood Marrow Transplant, vol.9, issue.4, pp.215-248, 2003.
URL : https://hal.archives-ouvertes.fr/hal-00849664

A. Kanate and B. Savani, Summary of scientific and statistical methods, study endpoints and definitions for observational and registry-based studies in hematopoietic cell transplantation, Clin Hematol Int, vol.2, issue.1, pp.2-4, 2020.

E. Kaplan and P. Mayer, Nonparametric estimation from incomplete observations, J Am Stat, vol.53, issue.282, pp.457-81, 2008.

P. Hougaard, Frailty models for survival data, Lifetime data analysis, vol.1, issue.3, pp.255-73, 1995.

P. K. Andersen, J. P. Klein, and M. J. Zhang, Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests, Statistics in medicine, vol.18, issue.12, pp.1489-500, 1999.

R. J. Soiffer, H. T. Kim, J. Mcguirk, M. E. Horwitz, L. Johnston et al., Prospective, randomized, double-blind, phase III clinical trial of anti-Tlymphocyte globulin to assess impact on chronic graft-versus-host diseasefree survival in patients undergoing HLA-matched unrelated myeloablative hematopoietic cell transplantation, J Clin Oncol, vol.35, issue.36, pp.4003-4014, 2017.

N. Kroger, C. Solano, C. Wolschke, G. Bandini, F. Patriarca et al., Antilymphocyte globulin for prevention of chronic graft-versus-host disease, N Engl J Med, vol.374, issue.1, pp.43-53, 2016.

L. Luznik, J. Bolanos-meade, M. Zahurak, A. R. Chen, B. D. Smith et al., High-dose cyclophosphamide as single-agent, short-course prophylaxis of graft-versus-host disease, Blood, vol.115, issue.16, pp.3224-3254, 2010.

Z. Peric, X. Cahu, P. Chevallier, E. Brissot, F. Malard et al., Features of Epstein-Barr Virus (EBV) reactivation after reduced intensity conditioning allogeneic hematopoietic stem cell transplantation, Leukemia, vol.25, issue.6, pp.932-940, 2011.

R. Crocchiolo, B. Esterni, L. Castagna, S. Furst, J. El-cheikh et al., Two days of antithymocyte globulin are associated with a reduced incidence of acute and chronic graft-versus-host disease in reduced-intensity conditioning transplantation for hematologic diseases, Cancer, vol.119, issue.5, pp.986-92, 2013.

F. Baron, M. Labopin, D. Blaise, L. Lopez-corral, S. Vigouroux et al., Impact of in vivo T-cell depletion on outcome of AML patients in first CR given peripheral blood stem cells and reduced-intensity conditioning allo-SCT from a HLA-identical sibling donor: a report from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation, Bone Marrow Transplant, vol.49, issue.3, pp.389-96, 2014.

A. Nagler, B. Dholaria, M. Labopin, G. Socie, A. Huynh et al., The impact of anti-thymocyte globulin on the outcomes of patients with AML with or without measurable residual disease at the time of allogeneic hematopoietic cell transplantation, Leukemia, vol.34, issue.4, pp.1144-53, 2020.

Y. Ofran, E. Beohou, M. Labopin, D. Blaise, J. J. Cornelissen et al., Antithymocyte globulin for graft-versus-host disease prophylaxis in patients with intermediate-or high-risk acute myeloid leukaemia undergoing reduced-intensity conditioning allogeneic stem cell transplantation in first complete remission -a survey on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation, Br J Haematol, vol.184, issue.4, pp.643-649, 2019.

M. Remberger, O. Ringden, H. Hagglund, B. M. Svahn, P. Ljungman et al., A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors, Clinical transplantation, vol.27, issue.4, pp.368-74, 2013.

R. Devillier, M. Labopin, P. Chevallier, M. P. Ledoux, G. Socie et al., Impact of antithymocyte globulin doses in reduced intensity conditioning before allogeneic transplantation from matched sibling donor for patients with acute myeloid leukemia: a report from the acute leukemia working party of European group of Bone Marrow Transplantation, Bone Marrow Transplant, vol.53, issue.4, pp.431-438, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02143554

, Publisher's Note

, Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations